The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis

Current Diabetes Reports

Volumn 16, Issue 10, 2016, Pages

  Needell, James C ^a   Zipris, Danny ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

16S rRNA; Inflammation; Kilham rat virus; Microbiome; Type 1 diabetes

Indexed keywords

TOLL LIKE RECEPTOR;

ANTIGEN RECOGNITION; AUTOIMMUNITY; CAUSAL ATTRIBUTION; CELL DESTRUCTION; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DYSBIOSIS; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; RAT MODEL; REVIEW; VIRUS PATHOGENESIS; ANIMAL; DIABETES MELLITUS, TYPE 1; INTESTINE; MICROBIOLOGY; PHYSIOLOGY; SYMBIOSIS;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; SYMBIOSIS; TOLL-LIKE RECEPTORS;

EID: 84982292027     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0781-z     Document Type: Review

References (91)

1. Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes. 2016;65(3):719–31. doi:10.2337/db15-0779.
2. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232–49.
3. de Beeck AO, Eizirik DL. Viral infections in type 1 diabetes mellitus—why the [beta] cells? Nat Rev Endocrinol. 2016;12(5):263–73. doi:10.1038/nrendo.2016.30.
4. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol. 2013;9(2):92–103.
5. Ghazarian L, Diana J, Simoni Y, Beaudoin L, Lehuen A. Prevention or acceleration of type 1 diabetes by viruses. Cell Mol Life Sci. 2012;70(2):239–55. doi:10.1007/s00018-012-1042-1.
6. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol. 2016;12(3):154–67. doi:10.1038/nrendo.2015.218. This excellent review article discusses recent advance made in the area of the gut microbiome and T1D.
7. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82. doi:10.1016/S0140-6736(13)60591-7.
8. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–33. doi:10.1016/S0140-6736(09)60568-7.
9. Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R. Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. BMJ: Br Med J. 1992;304(6833):1020–2.
10. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003;52(4):1052–5. doi:10.2337/diabetes.52.4.1052.
11. Zipris D. Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008;15(4):326–31.
12. Dotta F, Censini S, van Halteren AGS, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007;104(12):5115–20.
13. King ML, Bidwell D, Voller A, Bryant J, Banatvala JE. Role of Coxsackie B viruses in insulin-dependent diabetes mellitus. Lancet. 1983;2(8355):915–6.
14. King ML, Shaikh A, Bidwell D, Voller A, Banatvala JE. Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus. Lancet. 1983;1(8339):1397–9.
15. Zipris D. Epidemiology of type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms. Clin Immunol. 2009;131(1):11–23.
16. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev. 2003;19(1):8–31.
17. Jaeckel E, Manns M, von Herrath M. Viruses and diabetes. Ann N Y Acad Sci. 2002;958:7–25.
18. Chehadeh W, Weill J, Vantyghem M-C, Alm G, Lefebvre J, Wattre P, et al. Increased level of interferon-α in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J Infect Dis. 2000;181(6):1929–39.
19. Tanaka S, Nishida Y, Aida K, Maruyama T, Shimada A, Suzuki M, et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes. 2009;58(10):2285–91.
20. Uno S, Imagawa A, Saisho K, Okita K, Iwahashi H, Hanafusa T, et al. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J. 2010;57(11):991–6.
21. Lipman TH, Chang Y, Murphy KM. The epidemiology of type 1 diabetes in children in Philadelphia 1990–1994: evidence of an epidemic. Diabetes Care. 2002;25(11):1969–75.
22. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667–85. doi:10.1038/nri3738.
23. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141). doi:10.1126/science.1237439.
24. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol. 2009;7(12):887–94.
25. Verdu EF, Galipeau HJ, Jabri B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. Nat Rev Gastroenterol Hepatol. 2015;12(9):497–506. doi:10.1038/nrgastro.2015.90. http://www.nature.com/nrgastro/journal/v12/n9/abs/nrgastro.2015.90.html#supplementary-information.
26. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–35.
27. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79-R. doi:10.1186/gb-2012-13-9-r79.
28. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53(1):1–4. doi:10.1136/gut.53.1.1.
29. Veenbergen S, Samsom JN. Maintenance of small intestinal and colonic tolerance by IL-10-producing regulatory T cell subsets. Curr Opin Immunol. 2012;24(3):269–76. doi:10.1016/j.coi.2012.03.004.
30. Vaahtovuo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol. 2008;35(8):1500–5.
31. Sinkorova Z, Capkova J, Niederlova J, Stepankova R, Sinkora J. Commensal intestinal bacterial strains trigger ankylosing enthesopathy of the ankle in inbred B10.BR (H-2(k)) male mice. Hum Immunol. 2008;69(12):845–50. doi:10.1016/j.humimm.2008.08.296.
32. Bach JF. Infections and autoimmune diseases. J Autoimmun. 2005;25(Supplement 1):74–80.
33. Liu AH, Leung DYM. Renaissance of the hygiene hypothesis. J Allergy Clin Immunol. 2006;117(5):1063–6. doi:10.1016/j.jaci.2006.03.027.
34. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911–20. doi:10.1056/NEJMra020100.
35. de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13–27. doi:10.1038/nrgastro.2015.186. http://www.nature.com/nrgastro/journal/v13/n1/abs/nrgastro.2015.186.html#supplementary-information.
36. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
37. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675–80. doi:10.1038/90609.
38. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
39. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577–91. doi:10.1038/nrendo.2015.128.
40. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol. 2007;19(2):70–83. doi:10.1016/j.smim.2007.04.002.
41. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol. 2012;12(12):821–32.
42. Perez-Lopez A, Behnsen J, Nuccio S-P, Raffatellu M. Mucosal immunity to pathogenic intestinal bacteria. Nat Rev Immunol. 2016;16(3):135–48. doi:10.1038/nri.2015.17.
43. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–12. doi:10.1038/nrc3610.
44. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48. doi:10.1016/j.cell.2006.02.017.
45. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231–41.
46. Vaarala O. Leaking gut in type 1 diabetes. Curr Opin Gastroenterol. 2008;24(6):701–6. doi:10.1097/MOG.0b013e32830e6d98.
47. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620–5. http://www.nature.com/nature/journal/v453/n7195/suppinfo/nature07008_S1.html.
48. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332(6032):974–7. doi:10.1126/science.1206095.
49. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AGP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-[gamma] and RelA. Nat Immunol. 2004;5(1):104–12.
50. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303(5664):1662–5. doi:10.1126/science.1091334.
51. Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, et al. Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol. 2012;189(8):3805–14.
52. Mordes JP, Guberski DL, Leif JH, Woda BA, Flanagan JF, Greiner DL, et al. LEW.1WR1 rats develop autoimmune diabetes spontaneously and in response to environmental perturbation. Diabetes. 2005;54(9):2727–33.
53. Mordes JP, Zipris D, Liu Z, Blankenhorn EP. Viruses and autoimmune diabetes in rats. In: Taylor K, Hyöty H, Toniolo A, Zuckerman JA, editors. Diabetes and viruses. New York: Springer; 2013. p. 57–70.
54. Crisa L, Greiner DL, Mordes JP, MacDonald RG, Handler ES, Czech MP, et al. Biochemical studies of RT6 alloantigens in BB/Wor and normal rats. Evidence for intact unexpressed RT6a structural gene in diabetes-prone BB rats. Diabetes. 1990;39(10):1279–88.
55. Rossini AA, Handler ES, Mordes JP, Greiner DL. Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice--Caveat emptor. Clin Immunol Immunopathol. 1995;74(1):2–9.
56. Hara N, Alkanani A, Dinarello C, Zipris D. Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. J Mol Med. 2013:1–10.
57. Hara N, Alkanani AK, Dinarello CA, Zipris D. Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade. Innate Immun. 2014;20(6):574–84.
58. Wolter TR, Wong R, Sarkar SA, Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol. 2009;132(1):103–15.
59. Londono P, Komura A, Hara N, Zipris D. Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol. 2010;135(3):401–11.
60. Zipris D, Lien E, Xie JX, Greiner DL, Mordes JP, Rossini AA. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol. 2005;174(1):131–42.
61. Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia. 2006;49(9):2105–8.
62. Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, et al. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One. 2010;5(5), e10507. doi:10.1371/journal.pone.0010507.
63. Gill N, Finlay BB. The gut microbiota: challenging immunology. Nat Rev Immunol. 2011;11(10):636–7.
64. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–41.
65. Larsson E, Tremaroli V, Lee YS, Koren O, Nookaew I, Fricker A, et al. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut. 2012;61(8):1124–31.
66. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science. 2010;328(5975):228–31.
67. Ubeda C, Lipuma L, Gobourne A, Viale A, Leiner I, Equinda M, et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med. 2012;209(8):1445–56.
68. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455(7216):1109–13.
69. Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A. 1994;91(11):5138–42.
70. Devendra D, Jasinski J, Melanitou E, Nakayama M, Li M, Hensley B, et al. Interferon-{alpha} as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes. Diabetes. 2005;54(9):2549–56.
71. Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol. 2004;172(5):3173–80.
72. Alkanani AK, Hara N, Lien E, Ir D, Kotter CV, Robertson CE, et al. Induction of diabetes in the RIP-B7.1 mouse model is critically dependent on TLR3 and MyD88 pathways and is associated with alterations in the intestinal microbiome. Diabetes. 2014;63(2):619–31. doi:10.2337/db13-1007.
73. Hildebrandt MA, Hoffmann C, SherrilλGÇôMix SA, Keilbaugh SA, Hamady M, Chen Y, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137(5):1716–24.
74. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3(4):213–23.
75. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. doi:10.1038/nature05414.
76. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1(6):6ra14. doi:10.1126/scitranslmed.3000322.
77. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63. doi:10.1038/nature12820. This article describes the profound effect of diet on the gut bacterial composition.
78. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol. 2013;14(7):676–84. This article discusses how the gut microbiome influences the production of immunomodulatory, diet-dependent nutrients and metabolites and how these gut metabolites shape the immune system.
79. Wong JM, de Soure R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235–43.
80. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011;6, e25792.
81. de Goffau MC, Luopajärvi K, Knip M, Ilonen J, Ruohtula T, Härkönen T, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013;62(4):1238–44. doi:10.2337/db12-0526.
82. Davis-Richardson AG, Ardissone AN, Dias R, Simell V, Leonard MT, Kemppainen KM, et al. Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Front Microbiol. 2014;5:678. doi:10.3389/fmicb.2014.00678.
83. Kostic Aleksandar D, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen A-M, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. 2015;17(2):260–73. doi:10.1016/j.chom.2015.01.001.
84. de Goffau M, Fuentes S, van den Bogert B, Honkanen H, de Vos W, Welling G, et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia. 2014;57(8):1569–77.
85. Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes. 2015. doi:10.2337/db14-1847.
86. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.
87. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691–6.
88. Holmes E, Li J-á, Marchesi J-á, Nicholson J-á. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 2012;16(5):559–64.
89. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly Y, et al. The microbial metabolites, short-chain fatty acids, regulate colonic treg cell homeostasis. Science. 2013;341(6145):569–73.
90. Cole DK, Bulek AM, Dolton G, Schauenberg AJ, Szomolay B, Rittase W, et al. Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J Clin Invest. 2016;126(6):2191–204. doi:10.1172/JCI85679.
91. Costa FRC, Françozo MCS, de Oliveira GG, Ignacio A, Castoldi A, Zamboni DS, et al. Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset. J Exp Med. 2016;213(7):1223–39. doi:10.1084/jem.20150744.